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Mastitis is a one of the major diseases of dairy animals. Staphylococcus aureus is the most common microorganism associated 
with this dairy scourge. Cure rates of mastitis associated with this pathogen are appallingly low. Biofilm is an important virulence 
factor and immunogenic structure of S. aureus that makes it resistant to phagocytosis and antibiotics. Reports on the efficacy of 
vaccine prepared from a biofilm producing S. aureus are infrequent. The present study was designed to evaluate the role of a 
bacterin-toxoid prepared from a strong biofilm producing S. aureus in effective immunization of rabbits. The strong biofilm 
producing S. aureus selected from 64 isolates of staphylococci was used to prepare bacterin-toxoid and aluminum hydroxide gel was 
added as an adjuvant. The vaccine was evaluated in rabbits by challenge protection assay and humoral immune response. The 
mortality rates in control and vaccinated groups were 80% and 10% at day 7 post challenge and 100% and 20% at day 15 post 
challenge, respectively. Serum antibody titer (GMT) was significantly higher (294.0) in vaccinated group as compared to control 
group of rabbits (2.63) at day 45. The results showed that the vaccine has significantly elicited humoral immune response in rabbit 
and developed protective efficacy against new infections. 
 




Bovine mastitis is one of the most common infectious 
diseases of dairy animals that affects both quality and 
quantity of milk (Perez et al., 2009; Raza et al., 2013). 
Following the findings of field studies of economically 
substantial livestock diseases, mastitis is among the most 
important health problems of dairy animals (Hussain et 
al., 2005). Although mastitis can be caused by 137 
microorganisms (Fux et al., 2005; Ranjan et al., 2006), 
Staphylococcus aureus is considered to be the number 
one mastitis pathogen, other microorganisms which may 
be responsible for mastitis include Streptococcus 
agalactiae, Streptococcus uberis, Enterobacter 
aerogenes, Actinomyces pyogenes, Escherichia coli, 
Klebsiella spp., some mold and yeasts (Gruet et al., 
2001). 
Biofilm is a structural community of bacterial 
population in which they are enclosed and composed of 
self-produced polymeric matrix (Prakash et al., 2003; 
Fux et al., 2005). Biofilm production by S. aureus is an 
important virulence and immunogenic factor. Studies 
showed that biofilm producing bacteria exhibited 10-
1000 times resistance to antibiotics as compared to their 
counterpart planktonic bacteria (Olson et al., 2002; 
Melchior et al., 2007; Dhanawade et al., 2010). Isolates 
of S. aureus resistant to antibiotics and phagocytosis lead 
to failure of the treatment so the development of vaccines 
against mastitis to protect from new infections by S. 
aureus is of valuable interest to the commercial milk 
producers. Vaccines used against S. aureus give variable 
results depending upon nature of vaccine, adjuvants used 
and some other factors (Watson and Davies, 1993). 
An extensive variety of mastitis vaccines including 
inactivated bacteria with toxoid (Opdebeeck and 
Norcross, 1984), bivalent (S. aureus and S. agalactiae) 
bacterin-toxoid with aluminium hydroxide as adjuvant 
(Ahmad and Muhammad, 2008), bacteria encased in a 
mucous substance called a pseudo-capsule (Watson and 
Davies, 1993), capsular polysaccharide (CP) types CP5, 
CP8 and CP336 linked to protein carriers (von Eiff et al., 
2007) and a concoction of slime in liposomes, toxoid and 
different inactivated bacteria (Amorena et al., 1994) have 
been investigated 
Vaccines have revealed a considerable degree of 
protection against S. aureus mastitis. Recently, it was 
reported that bacterins from strong biofilm producing 
bacteria triggered the highest production of antibodies 
against Poly-N-acetylglucosamine (PNAG) and con-
ferred the highest protection against mastitis in sheep 
compared to weak biofilm producing strain (Perez et al., 
2009). It has been opined that a multicomponent vaccine 
incorporating a number of surface proteins and surface 
polysaccharides would prove to be more effective to 
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control mastitis in dairy animals (Schaffer and Lee, 
2008). 
There are limited reports available involving the role 
of biofilm in successful stimulation of protective immune 
response against S. aureus throughout the world. Based 
on these observations, the present study postulated that a 
mastitis vaccine prepared from a local strain of strong 
biofilm producing isolate of S. aureus could be effective, 
so the study was designed to evaluate the vaccine in 
rabbit model. 
 
Materials and Methods 
 
Isolation and identification of Staphylococcus 
aureus 
Surf Field Mastitis Test (Muhammad et al., 2010) 
positive milk samples were collected aseptically as per 
the guidelines of National Mastitis Council (NMC, 1990) 
after screening of study population (n=192 animals) in 
addition to a set of 14 milk samples submitted to the 
laboratory. 
The fresh samples were cultured and Staphylococcus 
isolates were presumptively identified following the 
standard guidelines (NMC, 1990). The staphylococcal 
isolates positive for tube coagulase test, protein A, 
clumping factor and certain exo-polysaccharides were 
further bio-typed by using a commercial identification kit 
(api® Staph). A 7 digit numeric profile (6716153) was 
generated using api® STAPH Identification Codebook by 
transforming the biochemical reactions on api® Staph kit 
into the numeral digits. 
 
Detection of biofilm production by Staphylo-
coccus aureus isolates 
All the isolates were subjected to tube method (TM) 
(Christensen et al., 1982) and micro-plate (MP) assay 
(Mathur et al., 2006) for qualitative and quantitative 
detection of biofilm production, respectively. Based on 
these two tests, 6 isolates were short listed to perform 
Congo red agar (CRA) method (Mathur et al., 2006) to 
further confirm the trait. The vaccine isolate S. aureus 
(C.B-732 RR) was selected on the basis of TM, MP and 
CRA (data not shown) and hemolytic pattern of the 
isolates (Table 1). 
Preparation of aluminum hydroxide adjuvanted 
bacterin-toxoid 
Strong biofilm producing isolate of S. aureus was 
selected as the candidate vaccine isolate. The vaccine 
was prepared by adopting the protocol as described 
earlier (Giraudo et al., 1997; Ahmad and Muhammad, 
2008). In order to provide the optimum cultural 
conditions, selected isolate of S. aureus was grown onto 
blood agar plates and then inoculated in modified 
nutrient broth (nutrient broth containing 10% w/v 
bubaline whey) for maximum encapsulation of S. aureus. 
The bacterial mass culture was inactivated with formalin 
(0.4% v/v) and the inactivated bacterial growth was 
centrifuged at 6,000 rpm for 30 min at 4°C. The 
supernatant was collected, autoclaved (121°C, 15 min) 
and stored at 4°C for further use as toxoid. The pellets of 
bacterial growth were re-suspended in phosphate buffer 
saline. The crude toxin extract (toxoid) and the 
preservatives (sodium azide 0.001% w/v, thimerosal 
sodium 0.001% w/v and formalin 0.4% v/v were added 
to the vaccine. Finally, aluminum hydroxide gel 
(Oxoid®) was added to the vaccine as an adjuvant and 
then final bacterial concentration was adjusted to 1 × 109 
cells/mL of vaccine using spectrophotometer. The 
vaccine was checked for sterility and safety by 
inoculating vaccine onto the different growth media and 
administration of vaccine to rabbits and dairy cow 
(Giraudo et al., 1997). 
 
Evaluation of bacterin-toxoid in rabbits 
Twenty five adult healthy rabbits were divided into 2 
groups (R1: control group included 10 rabbits and R2: 
vaccinated group included 15 rabbits). The rabbits in R1 
and R2 were administered with 2 shots of placebo and 
vaccine at a dose of 0.2 mL at thigh region through intra-
muscular route 15 days apart, respectively (Ahmad and 
Muhammad, 2008). The serum samples were collected 
from rabbits after every fortnight for a period of 2 
months post-vaccination (0, 15, 30, 45 and 60 days) and 
inactivated by heating in water bath at 56°C for 30 min 
(Rahman et al., 2005). 
At day 30 post second shot of vaccine, all rabbits of 
R1 (R1-1 thru R1-10) and 10 rabbits out of 15 of R2 
(R2-1 thru R2-10) were challenged by injecting the
 
Table 1: Selection criteria for a vaccine isolate 
Isolate I.D. TM score* MP score** CRA results** Hemolysis 
Cow-708 RR 2 0.275            Weak        β 
C.B-791 LF 3 0.227            Weak        β 
C.B-732 RR 3 0.298            Moderate        β 
Cow-138 LF+ 3 0.015            Strong        β 
Cow-474 RF++ 3 0.223            Moderate        Non-hemolytic 
Budhi Wachi RR+++ 0 0.132            Strong        β 
* Christensen et al. (1982) (basis for TM score: 0 = absent; 1 = weak; 2 = moderate; 3 = strong biofilm production), and ** Mathur et 
al. (2006); Basis for MP score: OD (570 nm) values measured by spectrophotometer and if OD>0.10 = None, OD 0.11-0.15 = weak, 
OD 0.16-0.25 = moderate and OD<0.26 = strong biofilm production. + Isolate was dropped from selection as in MP assay it was 
negative for biofilm production, ++ Isolate was strong biofilm producer in all tests but was non-hemolytic, and +++ Isolate was strong 
biofilm producer in CRA but negative in TM. Whereas LF means left front teat, LR means left rear teat, RF means right front teat 
and RR means right rear teat 
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active inoculum of S. aureus (1 × 109 cfu mL-1) at a dose 
of 0.2 mL through intra-peritoneal route. Five rabbits of 
R2 (R2-11 thru R2-15) were not challenged as they were 
used for serum collection at day 60 after second shot of 
vaccine. Both groups were monitored for mortality up to 
15 days post challenge. Indirect Hemagglutination (IHA) 
Test was performed for serological monitoring of 
antibodies against the bacterin-toxoid mastitis vaccine 
(Rahman et al., 2005). 
The research was conducted considering all the 
national and institutional legislations regarding animal 
protection and welfare. The use of the rabbits in the 
present experimental study was approved by the 
Directorates of Research and Advanced Studies and 




Geometric mean titers (GMT) were computed for 
both vaccinated and non-vaccinated control groups and 
then compared. Furthermore, cumulative mean titers and 
percentage values for challenge protection assay were 




Prevalence of mastitis and different pathogens 
The overall prevalence of clinical and sub-clinical 
mastitis in the study population was 48.44% (93/192 
animals). A total of 107 isolates of 6 different genera 
were recovered on microbiological examination (Table 
2). 
 
Safety and sterility of the vaccine 
The absence of any obvious growth on blood agar 
and MacConkey’s agar plates up to 48 h indicated that 
vaccine was sterile and free from any contamination. 
There was no local or systemic reaction in rabbits and
cow. 
 
Evaluation of vaccine in rabbits 
Challenge with live inoculums of vaccine isolate 
The vaccine showed a considerable survival rate in 
vaccinated group of rabbits compared to that of control 
group. The mortality rates and survival percentages in 
groups R1 and R2 are summarized in Table 3. 
 
Humoral immune response 
The GMT values of both groups are shown in Fig. 1. 
The antibody titer was highest (294.0) at day 45 which 
decreased gradually (111.4) at day 60 (Fig. 1). 
Cumulative mean titer was significantly higher in 
vaccinated group of rabbits (132.48) as compared to that 




It is now fairly well recognized that mastitis is one of 














Group R1 Group R2
 
 
Fig. 1: Comparison of humoral immune response in vaccinated 
and control (placebo control) groups of rabbits at different time 
points. Each data point shows the geometric mean titer (n=3) 
 
Table 2: Frequency distribution of micro-organisms (n=107 isolates) 
Pathogen/pathogen group No. of isolates Percentage (%) 
Staphylococcus aureus (coagulase positive at 4 h)                      43                   40.18 
Staphylococci (coagulase negative)                      21                   19.62 
Corynebacterium species                      15                   14.01 
Yeast                      13                   12.14 
Bacillus species                      7                   6.54 
Streptococcal species                      6                   5.60 
Coliforms                      2                   1.86 
 
Table 3: Results of challenge-protection assay at day 7 and 15 post vaccination 
Groups of rabbits R1 R2 
Vaccination dose and route   Placebo 0.2 ml I/M*    Bacterin-toxoid 0.2 ml I/M* 
Challenge dose (0.2 mL) and route of inoculation   Live inoculum (1 × 109 cells mL-1) I/P**    Live inoculum (1 × 109 cells mL-1) I/P** 
Total rabbits   10    10 
Rabbits died in 7 days   8    1 
No. of rabbits 
Rabbits died in 15 days   10    2 
Protection or survival (%) till day 7 post challenge   20    90 
Protection or survival (%) till day 15 post challenge   0    80 
Mortality (%) after 7 days   80    10 
Mortality (%) after 15 days   100    20 
* Intra-muscular, and ** Intra-peritoneal 
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world (Hortet and Seegers, 1998). Staphylococcus 
aureus has been reported as the most important mastitis 
pathogen in various countries across the world (Ali et al., 
2008; Kheirabadi et al., 2008; Sindhu et al., 2010). The 
results of present study indicated that S. aureus was the 
most prevalent microorganism in sub-clinical and 
clinical mastitis and the results are harmonious with 
previous studies (Gianneechini et al., 2002; Ericsson et 
al., 2009). Morphological and biochemical profile of the 
isolates coincided with previous reports (El-Jakee et al., 
2008). 
As S. aureus infections respond poorly to antibiotics, 
vaccines are considered as solid cavalry against this 
microorganism and focus is now on enhancing the 
production of specific antibodies against PNAG and 
pseudo-capsular antigens (Watson, 1992; Nordhaug et 
al., 1994). It has been reported that vaccines containing 
PNAG give considerable protective immune response 
and trigger antibodies production against S. aureus 
(Perez et al., 2009). The selected vaccine isolate was 
grown in modified nutrient broth to provide the optimum 
cultural conditions as reported in previous studies 
(Watson and Watson, 1989). The capsule and/or extra-
cellular glycocalyx is a polysaccharide which increases 
virulence of organism by impairing complement system 
and inhibiting antibody mediated opsonization (Fournier, 
1990). Glycocalyx expression is usually ceased when the 
bacteria is allowed to grow in ordinary growth media, 
however, addition of bubaline whey to nutrient broth 
enhances the expression of glycocalyx (Dalhof, 1985; 
Watson and Watson, 1989) which is a component of 
bacterial biofilms. Aluminum hydroxide was used as an 
adjuvant whereas it is well established that aluminum 
hydroxide is capable of eliciting protective immune 
response (Perez et al., 2009). All the procedures and 
protocols adopted for the development of bacterin-toxoid 
mastitis vaccine were in line with Giraudo et al. (1997) 
and Ahmad and Muhammad (2008). 
Dose dependent immune response can be elicited up 
to a definitive bacterial concentration depending upon 
type of bacteria and nature of adjuvant used (Opdebeeck 
and Norcross, 1985). Although vaccines for mastitis 
against S. aureus have been extensively studied, there are 
substantial improvements in production of different 
vaccines. In past times, the major aim of using vaccines 
was to decrease the intensity of disease caused by S. 
aureus as most vaccines were not protective against new 
infections (Chang et al., 2008; Middleton, 2008). 
Presently, with the advancement of new expertise, the 
major objective is to obtain greater degree of protection 
from novel infections. Some efforts have been made to 
develop vaccines containing purified PNAG capable of 
inducing some degree of protection against S. aureus 
new infections in sheep while it failed to stop the 
establishment of new infections in cows (Perez et al., 
2009; Prenafeta et al., 2010). The challenge protection 
assay showed a considerable protective immune response 
in rabbits. The findings were in agreement with Giraudo 
et al. (1997) and Ahmad and Muhammad (2008) with 
significantly higher survival percentage in vaccinated 
rabbits compared to that of rabbits in control group. The 
fallouts of challenge protection assay suggested that 
vaccine is capable of eliciting protective immune 
response and prevent further new infections of S. aureus. 
Recently, it has been shown that vaccines containing 
PNAG induce strong antibody production in mouse 
model and cows (Perez et al., 2009; Prenafeta et al., 
2010). Previous studies showed that bacterin-toxoid 
prevent development of new S. aureus infection in cows 
probably due to increased opsonization, increased 
phagocytic activity of polymorphonuclear cells as a 
result of augmented specific IgG antibodies against S. 
aureus in serum and milk (Watson, 1976; Pellegrino et 
al., 2010). The chronological production of antibodies 
against biofilm producer S. aureus was increasing from 
day 1 up to day 45 and then followed by a plummet at 
day 60. Recently, it was shown that vaccine prepared 
from biofilm producing S. aureus produce significantly 
higher IgG level in rabbits as compared to that of free 
cell S. aureus vaccines and the study showed clear 
superiority of biofilm cells vaccine over free cells 
vaccine (Rathnamma, 2013). Similar type of antibody 
production response has been reported using biofilm 
producing E. coli vaccine in rabbits (Jyothi, 2013). The 
upshots of the study were in agreement with that of Han 
and Park (2000) who also observed a similar type of 
immune response against S. aureus in rabbits. The 
highest immune response was observed at days 30 and 
45 post vaccination whereas some previous studies 
showed the highest immune response at days 45 and 60 
(Han and Park, 2000; Ahmad and Muhammad, 2008) in 
rabbits. The vaccine prepared from strong biofilm 
producing isolate of S. aureus showed more effective 
results in challenge protection assay and a four-fold 
increase in serum antibody titer (GMT) when compared 
to the outcomes of a previous study (Ahmad and 
Muhammad, 2008) in which our laboratory workers used 
isolate of S. aureus (api® STAPH numeric profile 
6736153) that showed weak biofilm production when 
evaluated for biofilm production in the present study 
(data will be published in separate publication). 
The results of the study showed an increased 
antibody production in vaccinated group that was 
capable of preventing establishment of new S. aureus 
infection in rabbits as compared control group. Based on 
the results of present study, a short term clinical trial was 
conducted in dairy cows and buffaloes which also 
showed effectiveness of vaccine indicated by significant 
difference in prevalence and incidence of mastitis, high 
level of variation in microbiological examination of 
milk, reduced intra-mammary infections and somatic cell 
counts between vaccinated and control group of dairy 
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